American Society of Clinical Oncology Clinical Practice Guideline: Update on Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer

This publication has 85 references indexed in Scilit:

• Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial
  The Lancet Oncology, 2008
• Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors
  Breast Cancer Research and Treatment, 2007
• Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98
  Breast Cancer Research and Treatment, 2007
• Letrozole in the extended adjuvant setting: MA.17
  Breast Cancer Research and Treatment, 2007
• Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
  The Lancet, 2007
• Early discontinuation of tamoxifen
  Cancer, 2007
• Quality of Life of Postmenopausal Women in the ATAC (“Arimidex”, Tamoxifen, Alone or in Combination) Trial after Completion of 5 years' Adjuvant Treatment for Early Breast Cancer
  Breast Cancer Research and Treatment, 2006
• Adjuvant systemic therapy for male breast carcinoma
  Cancer, 2005
• Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
  The Lancet, 2005
• Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial
  The Lancet, 2002